SCHEMBL4847804

SCHEMBL4847804

CN(C)CCOc1ccc(-c2ccccc2C(F)(F)F)cc1C=CC(=O)c1ccccc1CN(C)C

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
UTS2R Q9UKP6 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
HRH1 P35367 1/20 0.38
RBP4 P02753 1/20 0.37
SLC6A9 P48067 3/20 0.37
RXFP1 Q9HBX9 1/20 0.37
FFAR4 Q5NUL3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4847800 0.90 SMN1; SMN2 (0.45) MAOBSMN1; SMN2LMNAGAAMAPT
SCHEMBL4857391 0.90 SMN1; SMN2 (0.45) MAOBSMN1; SMN2LMNAGAAMAPT
SCHEMBL4854762 0.89 ALDH1A1 (0.42) MAOBSMN1; SMN2KDM4EALDH1A1HRH1
SCHEMBL4851092 0.88 ALDH1A1 (0.42) SMN1; SMN2KDM4EALDH1A1HRH1SLC6A9
SCHEMBL4847450 0.87 SLC6A9 (0.43) SMN1; SMN2KDM4EALDH1A1HRH1SLC6A9
SCHEMBL4848073 0.87 HTR7 (0.41) MAOBSMN1; SMN2UTS2RKDM4EALDH1A1
SCHEMBL4853598 0.87 MAOB (0.41) MAOBSMN1; SMN2KDM4EALDH1A1HRH1
SCHEMBL4848106 0.86 SLC6A9 (0.44) SMN1; SMN2KDM4EALDH1A1HRH1SLC6A9
SCHEMBL6394376 0.86 HTR7 (0.46) MAOBSMN1; SMN2KDM4EALDH1A1HRH1
SCHEMBL4847477 0.86 ALDH1A1 (0.40) MAOBSMN1; SMN2KDM4EALDH1A1HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423181-B2 in particular against bacterial and parasitic infections, fungi, and helminths; improved metabolic and physiochemical properties, bioavailability, solubility; 3-[4-(2-Dimethylamino-ethoxy)-2'-trifluoromethyl-biphenyl-3-yl]-1-(2-dimethylaminomethyl-phenyl)-propenone LICA PHARMACEUTICALS A/S (DK) 2008-09-09 US claimed
US-20050227990-A1 Aminoalkoxy-functional chalcones LICA PHARMACEUTICALS A/S (DK) 2005-10-13 US claimed
US-7423181-B2 in particular against bacterial and parasitic infections, fungi, and helminths; improved metabolic and physiochemical properties, bioavailability, solubility; 3-[4-(2-Dimethylamino-ethoxy)-2'-trifluoromethyl-biphenyl-3-yl]-1-(2-dimethylaminomethyl-phenyl)-propenone LICA PHARMACEUTICALS A/S (DK) 2008-09-09 US disclosed
US-20050227990-A1 Aminoalkoxy-functional chalcones LICA PHARMACEUTICALS A/S (DK) 2005-10-13 US disclosed